Real-time enrollment status for this anthracycline related cardiotoxicity in breast cancer clinical trial
Current Status
Recruiting
Checked: July 22, 2026 at 9:04 PM UTC
| NCT Number | NCT03934905 |
| Recruiting Status | Recruiting |
| Condition | Anthracycline Related Cardiotoxicity in Breast Cancer |
| Phase | PHASE1 |
| Target Enrollment | 70 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Texas Tech University Health Sciences Center |
| Last Updated on CT.gov | June 29, 2026 (3 weeks ago) |
As of July 22, 2026: Clinical trial NCT03934905 is currently recruiting participants. This phase1 study for anthracycline related cardiotoxicity in breast cancer is actively seeking new participants at 1 location across the United States. The study is sponsored by Texas Tech University Health Sciences Center. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT03934905 is actively recruiting participants as of July 22, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT03934905 was last updated 3 weeks ago (June 29, 2026). HelloStudys verifies this status automatically.